Vericel Co. (NASDAQ:VCEL) Shares Purchased by Federated Hermes Inc.

Federated Hermes Inc. lifted its holdings in shares of Vericel Co. (NASDAQ:VCEL) by 25.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,122,373 shares of the biotechnology company’s stock after acquiring an additional 227,675 shares during the quarter. Federated Hermes Inc. owned about 2.27% of Vericel worth $61,630,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Meeder Asset Management Inc. lifted its stake in shares of Vericel by 8.4% during the fourth quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 183 shares in the last quarter. Atria Investments Inc lifted its position in Vericel by 2.4% during the 4th quarter. Atria Investments Inc now owns 7,952 shares of the biotechnology company’s stock worth $437,000 after acquiring an additional 184 shares in the last quarter. Louisiana State Employees Retirement System grew its position in Vericel by 0.8% in the fourth quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company’s stock valued at $1,312,000 after acquiring an additional 200 shares in the last quarter. Avantax Advisory Services Inc. raised its stake in shares of Vericel by 1.7% during the fourth quarter. Avantax Advisory Services Inc. now owns 13,803 shares of the biotechnology company’s stock valued at $758,000 after purchasing an additional 234 shares during the period. Finally, Linden Thomas Advisory Services LLC lifted its position in shares of Vericel by 1.1% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 43,781 shares of the biotechnology company’s stock worth $2,404,000 after purchasing an additional 489 shares in the last quarter.

Analysts Set New Price Targets

VCEL has been the topic of several analyst reports. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. Stephens reaffirmed an “overweight” rating and set a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. Truist Financial reissued a “buy” rating and issued a $61.00 price target (down previously from $67.00) on shares of Vericel in a report on Monday, March 3rd. Canaccord Genuity Group upped their target price on Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Vericel in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Vericel has a consensus rating of “Moderate Buy” and an average target price of $62.29.

Vericel Stock Down 3.6 %

NASDAQ:VCEL opened at $41.92 on Monday. Vericel Co. has a 52 week low of $39.12 and a 52 week high of $63.00. The company has a market cap of $2.10 billion, a PE ratio of 698.78 and a beta of 1.61. The business’s 50 day moving average is $51.74 and its two-hundred day moving average is $51.73.

Insider Buying and Selling

In other Vericel news, CEO Dominick Colangelo sold 26,592 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $45.78, for a total value of $1,217,381.76. Following the transaction, the chief executive officer now owns 259,997 shares of the company’s stock, valued at $11,902,662.66. This trade represents a 9.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jonathan Siegal sold 3,908 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total value of $242,256.92. Following the transaction, the insider now directly owns 1,206 shares of the company’s stock, valued at $74,759.94. This trade represents a 76.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 34,092 shares of company stock worth $1,683,582 over the last ninety days. 5.20% of the stock is owned by insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.